{"protocolSection":{"identificationModule":{"nctId":"NCT02486718","orgStudyIdInfo":{"id":"GO29527"},"secondaryIdInfos":[{"id":"2014-003205-15","type":"EUDRACT_NUMBER"},{"id":"2023-505981-26-00","type":"REGISTRY","domain":"CTIS (EU)"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","officialTitle":"A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-10-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-01-26","type":"ACTUAL"},"completionDateStruct":{"date":"2035-08-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-06-04","studyFirstSubmitQcDate":"2015-06-26","studyFirstPostDateStruct":{"date":"2015-07-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2024-12-12","resultsFirstSubmitQcDate":"2025-03-27","resultsFirstPostDateStruct":{"date":"2025-03-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-30","lastUpdatePostDateStruct":{"date":"2025-10-10","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1280,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Atezolizumab","type":"EXPERIMENTAL","description":"Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \\[non-squamous cell NSCLC only\\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.","interventionNames":["Drug: Atezolizumab","Drug: Cisplatin","Drug: Vinorelbine","Drug: Docetaxel","Drug: Gemcitabine","Drug: Pemetrexed"]},{"label":"Best Supportive Care","type":"ACTIVE_COMPARATOR","description":"Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \\[non-squamous cell NSCLC only\\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.","interventionNames":["Drug: Cisplatin","Drug: Vinorelbine","Drug: Docetaxel","Drug: Gemcitabine","Drug: Pemetrexed"]}],"interventions":[{"type":"DRUG","name":"Atezolizumab","description":"Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).","armGroupLabels":["Atezolizumab"],"otherNames":["MPDL3280A; TECENTRIQ"]},{"type":"DRUG","name":"Cisplatin","description":"Participants will receive cisplatin 75 milligrams per square meter (mg/m\\^2) IV on Day 1 of up to four 21-day cycles.","armGroupLabels":["Atezolizumab","Best Supportive Care"]},{"type":"DRUG","name":"Vinorelbine","description":"Participants will receive vinorelbine 30 mg/m\\^2 IV on Days 1 and 8 of each of the four 21-day cycles.","armGroupLabels":["Atezolizumab","Best Supportive Care"]},{"type":"DRUG","name":"Docetaxel","description":"Participants will receive docetaxel 75 mg/m\\^2 IV on Day 1 of each of the four 21-day cycles.","armGroupLabels":["Atezolizumab","Best Supportive Care"]},{"type":"DRUG","name":"Gemcitabine","description":"Participants will receive gemcitabine 1250 mg/m\\^2 IV on Days 1 and 8 of each of the four 21-day cycles.","armGroupLabels":["Atezolizumab","Best Supportive Care"]},{"type":"DRUG","name":"Pemetrexed","description":"Participants will receive pemetrexed 500 mg/m\\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.","armGroupLabels":["Atezolizumab","Best Supportive Care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","timeFrame":"Up to 95 months"},{"measure":"DFS in All Randomized Stage II-IIIA Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in participants with disease stage II-IIIA. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","timeFrame":"Up to 95 months"},{"measure":"DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 ≥1% subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","timeFrame":"Up to 95 months"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS) in the ITT Population","description":"OS was defined as the time from randomization to death from any cause.","timeFrame":"Up to 20 years"},{"measure":"Disease-free Rate at Year 3 in ITT Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 3. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","timeFrame":"Year 3"},{"measure":"Disease-free Rate at Year 3 in All Randomized Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","timeFrame":"Year 3"},{"measure":"Disease-free Rate at Year 3 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","timeFrame":"Year 3"},{"measure":"Disease-free Rate at Year 5 in ITT Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","timeFrame":"Year 5"},{"measure":"Disease-free Rate at Year 5 in All Randomized Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","timeFrame":"Year 5"},{"measure":"Disease-free Rate at Year 5 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","timeFrame":"Year 5"},{"measure":"DFS in the PD-L1 (SP263 ≥ 50% TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","timeFrame":"Up to 95 months"},{"measure":"Percentage of Participants With Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a participant when administered a pharmaceutical product regardless of the causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.","timeFrame":"Up to 20 years"},{"measure":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab","description":"The percentage of ATA (Also called anti-drug antibodies (ADA))-positive participants after drug administration were determined for participants exposed to atezolizumab. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.","timeFrame":"Predose (Hour 0) on Day 1 of Cycles 2, 3, 4, 8, 16 (Cycle length = 21 days), at treatment discontinuation (TD) (up to 12 months), 120 days after last atezolizumab administration (up to 16 months)"},{"measure":"Maximum Plasma Concentration (Cmax) of Atezolizumab","timeFrame":"30 min post-infusion on Day 1 of Cycle 1 (Cycle length = 21 days)"},{"measure":"Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab","timeFrame":"Prior to infusion on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (Cycle length = 21 days), at study discontinuation visit (up to 12 months), Day 120 post last dose of atezolizumab (up to 16 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion Criteria for Enrollment Phase\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histological or cytological diagnosis of Stage IB (tumors greater than or equal to \\[\\>/=\\] 4 centimeters \\[cm\\])-IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) NSCLC (per the Union Internationale Contre le Cancer staging system (UICC)/American Joint Committee on Cancer staging system (AJCC) staging system, 7th edition; Detterbeck et al. 2009)\n* Participants must have had complete resection of NSCLC 4-12 weeks (\\>/=28 days and less than or equal to \\[\\</=\\] 84 days) prior to enrollment and must be adequately recovered from surgery\n* If mediastinoscopy was not performed preoperatively, it is required that, at a minimum, mediastinal lymph node systematic sampling will have occurred. Systematic sampling is defined as removal of at least one representative lymph node at specified levels. MLND entails resection of all lymph nodes at those same levels. For a right thoracotomy, sampling or MLND is required at levels 4 and 7 and for a left thoracotomy, levels 5 and/or 6 and 7. Exceptions will be granted if there is clear documentation in the operative report or in a separately submitted addendum by the surgeon of exploration of the required lymph node areas, the participant will be considered eligible if no lymph nodes are found in those areas; if participants have documented N2 disease in one level (per the UICC/AJCC staging system, 7th edition; Detterbeck et al. 2009), not all levels need to be sampled; if the preoperative staging imaging results (contrast computed tomography \\[CT\\] and positron emission tomography \\[PET\\] scans) do not suggest evidence of disease in the mediastinum, the participant will be considered eligible if N2 nodal sampling is not performed per surgeon's decision\n* Eligible to receive a cisplatin-based chemotherapy regimen\n* Adequate hematologic and end-organ function\n* Women who are not postmenopausal (\\>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of cisplatin-based chemotherapy\n\nInclusion Criteria for Randomized Phase - Women who are not postmenopausal (\\>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of atezolizumab or BSC\n\nExclusion Criteria:\n\nExclusion Criteria for Enrollment Phase\n\n* Illness or condition that may interfere with a participant's capacity to understand, follow, and/or comply with study procedures\n* Pregnant and lactating women\n* Treatment with prior systemic chemotherapy: Chemotherapy for early stage of malignancy with curative intent, provided that the last dose received was more than 5 years prior to enrollment and low-dose chemotherapy for non-malignant conditions may be allowed upon approval by the Medical Monitor\n* Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years before enrollment\n* Treatment with any other investigational agent with therapeutic intent within 28 days prior to enrollment\n* Participants with hearing impairment\n* Known sensitivity to any component of the chemotherapy regimen the participant will be assigned to, or to mannitol\n* Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti programmed death ligand 1 (PD-L1) therapeutic antibodies\n* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS greater than \\[\\>\\] 90 percent \\[%\\]) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation\n* History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n* Positive test for human immunodeficiency virus (HIV)\n* Participants with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C\n* Active tuberculosis\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within the previous 3 months, unstable arrhythmias, or unstable angina\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan\n* Prior allogeneic bone marrow transplantation or solid organ transplant\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications\n* Known tumor PD-L1 expression status as determined by an immunohistochemistry (IHC) assay from other clinical studies (e.g., participants whose PD-L1 expression status was determined during screening for entry into a study with anti-PD-1 or anti-PD-L1 antibodies but were not eligible are excluded)\n\nSpecific Exclusions for Pemetrexed Treatment\n\n\\- Participants with squamous cell histology\n\nExclusion Criteria for Randomized Phase\n\n* Signs or symptoms of infection within 14 days prior to randomization (severe infection within 28 days prior to randomization), including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to randomization\n* Major surgical procedure within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study\n* Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live attenuated vaccine will be required during the study\n* Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to randomization: Prior treatment with cancer vaccines is allowed\n* Treatment with systemic corticosteroids or other immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 14 days prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Highlands Oncology Group","city":"Fayetteville","state":"Arkansas","zip":"72703","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"California Cancer Associates for Research & Excellence, Inc.","city":"Encinitas","state":"California","zip":"92024","country":"United States","geoPoint":{"lat":33.03699,"lon":-117.29198}},{"facility":"Compassionate Cancer Care Medical Group, Inc","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"University of California Los Angeles","city":"Los Angeles","state":"California","zip":"90024","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Kaiser Permanente","city":"Vallejo","state":"California","zip":"94589","country":"United States","geoPoint":{"lat":38.10409,"lon":-122.25664}},{"facility":"Kaiser Permanente - Walnut Creek","city":"Walnut Creek","state":"California","zip":"94596","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Eastern Connecticut Hematology and Oncology Associates","city":"Norwich","state":"Connecticut","zip":"06360","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"facility":"Lynn Cancer Institute - West","city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"University of Miami School of Medicine - Sylvester at Deerfield","city":"Deerfield Beach","state":"Florida","zip":"33442","country":"United States","geoPoint":{"lat":26.31841,"lon":-80.09977}},{"facility":"SCRI Florida Cancer Specialists North","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Lewis Hall Singletary Oncology Center","city":"Thomasville","state":"Georgia","zip":"31792","country":"United States","geoPoint":{"lat":30.83658,"lon":-83.97878}},{"facility":"University of Illinois at Chicago","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Illinois Cancer Care","city":"Peoria","state":"Illinois","zip":"61615","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Norton Cancer Institute","city":"Louisville","state":"Kentucky","zip":"40402","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"St. Luke's Cancer Institute","city":"Kansas City","state":"Missouri","zip":"64111","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Hematology Oncology Associates of Northern New Jersey","city":"Florham Park","state":"New Jersey","zip":"07932","country":"United States","geoPoint":{"lat":40.78788,"lon":-74.38821}},{"facility":"Saint Barnabas Medical Center","city":"Livingston","state":"New Jersey","zip":"07039","country":"United States","geoPoint":{"lat":40.79593,"lon":-74.31487}},{"facility":"Valley Hospital","city":"Paramus","state":"New Jersey","zip":"07652","country":"United States","geoPoint":{"lat":40.94454,"lon":-74.07542}},{"facility":"Overlook Medical Center","city":"Summit","state":"New Jersey","zip":"07901","country":"United States","geoPoint":{"lat":40.71562,"lon":-74.36468}},{"facility":"Clinical Research Alliance","city":"Lake Success","state":"New York","zip":"11042","country":"United States","geoPoint":{"lat":40.77066,"lon":-73.71763}},{"facility":"Weill Cornell Medical College","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Presbyterian Hospital","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"University of Cincinnati","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Oncology Hematology Care - SCRI","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Oregon Health and Science University","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"University Oncology Associates","city":"Chattanooga","state":"Tennessee","zip":"37403","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Houston Methodist Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Wellmont Medical Associates","city":"Bristol","state":"Virginia","zip":"24201","country":"United States","geoPoint":{"lat":36.59649,"lon":-82.18847}},{"facility":"Hematology Oncology Associates of Fredericksburg, Inc.","city":"Fredericksburg","state":"Virginia","zip":"22408","country":"United States","geoPoint":{"lat":38.30318,"lon":-77.46054}},{"facility":"MultiCare Regional Cancer Center - Auburn","city":"Auburn","state":"Washington","zip":"98002-4117","country":"United States","geoPoint":{"lat":47.30732,"lon":-122.22845}},{"facility":"Providence Everett Med Ctr","city":"Everett","state":"Washington","zip":"98201","country":"United States","geoPoint":{"lat":47.97898,"lon":-122.20208}},{"facility":"Swedish Medical Center","city":"Seattle","state":"Washington","zip":"98122","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Townsville Hospital","city":"Douglas","state":"Queensland","zip":"4814","country":"Australia","geoPoint":{"lat":-19.32394,"lon":146.75234}},{"facility":"Cabrini Hospital Malvern","city":"Malvern","state":"Victoria","zip":"3144","country":"Australia","geoPoint":{"lat":-37.86259,"lon":145.02811}},{"facility":"Cliniques Universitaires St-Luc","city":"Brussels","zip":"1200","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"CHU de Liège (Sart Tilman)","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Cancer Institute and Hospital Chinese Academy of Medical Sciences","city":"Beijing","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The First Affiliated Hospital of Guangzhou Medical University","city":"Guangzhou","zip":"510120","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Zhejiang Cancer Hospital","city":"Hangzhou","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Anhui Province Cancer Hospital","city":"Hefei","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Shanghai Chest Hospital","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Shanghai Pulmonary Hospital","city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Liaoning Provincial Cancer Hospital","city":"Shengyang","zip":"110042","country":"China","geoPoint":{"lat":36.2001,"lon":104.546}},{"facility":"First Hospital of China Medical University","city":"Shenyang","zip":"110001","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"First Affiliated Hospital of Soochow University","city":"Suzhou","zip":"215006","country":"China","geoPoint":{"lat":31.30408,"lon":120.59538}},{"facility":"Centre Hospitalier de Mont de Marsan - Hopital Layne","city":"Mont-de-Marsan","zip":"40000","country":"France","geoPoint":{"lat":43.89022,"lon":-0.49713}},{"facility":"Clinique Clémentville","city":"Montpellier","zip":"34070","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque","city":"Montpellier","zip":"34298","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique","city":"Nantes","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Centre Hospitalier Regional Sud Reunion","city":"Saint-Pierre","zip":"97448","country":"France","geoPoint":{"lat":43.29282,"lon":5.40682}},{"facility":"Centre Hospitalier de Saint-Quentin","city":"Saint-Quentin","zip":"02321","country":"France","geoPoint":{"lat":49.84889,"lon":3.28757}},{"facility":"Hopital d Instruction des Armees de Sainte Anne","city":"Toulon","zip":"83041","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Ev.Krankenhaus Bielefeld gGmbH","city":"Bielefeld","state":"North Rhine-Westphalia","zip":"33611","country":"Germany","geoPoint":{"lat":52.03333,"lon":8.53333}},{"facility":"Evang. Lungenklinik Berlin Klinik für Pneumologie","city":"Berlin","zip":"13125","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Stadtisches Klinikum Braunschweig","city":"Braunschweig","zip":"38114","country":"Germany","geoPoint":{"lat":52.26594,"lon":10.52673}},{"facility":"Klinikum Chemnitz gGmbH","city":"Chemnitz","zip":"09113","country":"Germany","geoPoint":{"lat":50.8357,"lon":12.92922}},{"facility":"Krankenhaus Nordwest","city":"Frankfurt am Main","zip":"60488","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"LungenClinic Grosshansdorf GmbH","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Lungenklinik Hemer","city":"Hemer","zip":"58675","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"Universität Des Saarlandes","city":"Homburg","zip":"66421","country":"Germany","geoPoint":{"lat":49.32637,"lon":7.33867}},{"facility":"Fachklinik für Lungenerkrankungen","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Vincentius-Diakonissen-Kliniken gAG","city":"Karlsruhe","zip":"76137","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"facility":"Katholisches Klinikum Marienhof","city":"Koblenz Am Rhein","zip":"56073","country":"Germany"},{"facility":"Klinikum Bogenhausen","city":"München","zip":"81925","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Gemeinschaftspraxis für Hämatologie und Onkologie","city":"Münster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Pius-Hospital Oldenburg","city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Krankenhaus Barmherzige Bruder Regensburg","city":"Regensburg","zip":"93049","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Prince of Wales Hosp","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"University of Pecs, I st Dept of Internal Medicine","city":"Pécs","zip":"7624","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"facility":"Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.","city":"Szolnok","zip":"5004","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Rambam Medical Center","city":"Haifa","zip":"31096","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Edith Wolfson Medical Center","city":"Holon","zip":"58100","country":"Israel","geoPoint":{"lat":32.01034,"lon":34.77918}},{"facility":"Meir Medical Center","city":"Kfar Saba","zip":"44281","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Tel Aviv Sourasky Medical Ctr","city":"Tel Aviv","zip":"64239","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Chaim Sheba Medical Center","city":"Tel Litwinsky","zip":"52621","country":"Israel","geoPoint":{"lat":32.05096,"lon":34.84588}},{"facility":"Ospedale Clinicizzato SS Annunziata","city":"Chieti","state":"Abruzzo","zip":"66013","country":"Italy","geoPoint":{"lat":42.34827,"lon":14.16494}},{"facility":"Azienda per l'Assistenza Sanitaria N° 5 - Friuli Occidentale","city":"Pordenone","state":"Friuli Venezia Giulia","zip":"33170","country":"Italy","geoPoint":{"lat":45.95689,"lon":12.66051}},{"facility":"Policlinico Universitario Campus Biomedico Di Roma","city":"Rome","state":"Lazio","zip":"00128","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Asst Papa Giovanni XXIII","city":"Bergamo","state":"Lombardy","zip":"24127","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"facility":"ASST Spedali Civili di Brescia","city":"Brescia","state":"Lombardy","zip":"25123","country":"Italy","geoPoint":{"lat":45.53558,"lon":10.21472}},{"facility":"Azienda Sanitaria Ospedaliera S Luigi Gonzaga","city":"Orbassano","state":"Piedmont","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Azienda Ospedaliera Città della Salute e della Scienza di Torino","city":"Turin","state":"Piedmont","zip":"10126","country":"Italy","geoPoint":{"lat":45.07049,"lon":7.68682}},{"facility":"Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi","city":"Catania","state":"Sicily","zip":"95122","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Ospedale Santa Chiara","city":"Trento","state":"Trentino-Alto Adige","zip":"38100","country":"Italy","geoPoint":{"lat":46.06787,"lon":11.12108}},{"facility":"Azienda Ospedaliero Universitaria Pisana","city":"Pisa","state":"Tuscany","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Ospedale Silvestrini","city":"Perugia","state":"Umbria","zip":"06132","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Azienda Ospedaliera Universitaria Integrata Verona","city":"Verona","state":"Veneto","zip":"37126","country":"Italy","geoPoint":{"lat":45.43854,"lon":10.9938}},{"facility":"Aichi Cancer Center Hospital","city":"Aichi","zip":"464-8681","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"Hyogo Cancer Center","city":"Akashi","zip":"673-0021","country":"Japan","geoPoint":{"lat":34.65524,"lon":135.00687}},{"facility":"Juntendo University Hospital","city":"Bunkyō City","zip":"113-8431","country":"Japan","geoPoint":{"lat":35.5331,"lon":139.4217}},{"facility":"Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital","city":"Bunkyō City","zip":"113-8677","country":"Japan","geoPoint":{"lat":35.5331,"lon":139.4217}},{"facility":"National Cancer Center Hospital","city":"Chūō","zip":"104-0045","country":"Japan","geoPoint":{"lat":35.67004,"lon":139.77544}},{"facility":"Kyushu University Hospital","city":"Fukuoka","zip":"812-8582","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Hiroshima University Hospital","city":"Hiroshima","zip":"734-8551","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Saitama Cancer Center","city":"Kitaadachi-gun","zip":"362-0806","country":"Japan"},{"facility":"Hospital of the University of Occupational and Environmental Health,Japan","city":"Kitakyushu-shi","zip":"807-8555","country":"Japan"},{"facility":"Kumamoto University Hospital","city":"Kumamoto","zip":"860-8556","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69181}},{"facility":"Kyoto University Hospital","city":"Kyoto","zip":"606-8507","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Shikoku Cancer Center","city":"Matsuyama","zip":"791-0280","country":"Japan","geoPoint":{"lat":33.83916,"lon":132.76574}},{"facility":"Kyorin University Hospital","city":"Mitaka-shi","zip":"181-0004","country":"Japan"},{"facility":"Niigata Cancer Center Hospital","city":"Niigata","zip":"951-8566","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Okayama University Hospital","city":"Okayama","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"National Hospital Organization Hokkaido Cancer Center","city":"Sapporo","zip":"003-0804","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Toranomon Hospital","city":"Tokyo","zip":"105-8470","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Tokyo Medical University Hospital","city":"Tokyo","zip":"160-0023","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Kanagawa Cancer Center","city":"Yokohama-shi, Asahi-ku","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Jeroen Bosch Ziekenhuis","city":"'s-Hertogenbosch","state":"North Brabant","zip":"5223 GZ","country":"Netherlands","geoPoint":{"lat":51.69917,"lon":5.30417}},{"facility":"St. Antonius Ziekenhuis Nieuwegein","city":"Nieuwegein","zip":"3430 EM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu","city":"Poznan","zip":"60569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Centro Hospitalar E Universitário de Coimbra EPE","city":"Coimbra","zip":"3000-602","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Hospital de Sao Joao","city":"Porto","zip":"4200-319","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Oncology Center Sf. Nectarie","city":"Craiova","zip":"200542","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Principal Military Clinical Hospital n.a. N.N. Burdenko","city":"Moscow","state":"Moscow Oblast","zip":"105229","country":"Russia"},{"facility":"Leningrad Regional Clinical Hospital","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Scientific Research Institute of Oncology n.a. N.N. Petrov","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"City Clinical Hospital #1","city":"Novosibirsk","zip":"630047","country":"Russia","geoPoint":{"lat":55.02259,"lon":82.93175}},{"facility":"Volgograd Regional Clinical Oncology Dispensary","city":"Volgograd","zip":"400138","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"Regional Clinical Oncology Hospital","city":"Yaroslavl","zip":"150040","country":"Russia","geoPoint":{"lat":57.62987,"lon":39.87368}},{"facility":"Chonnam National University Hwasun Hospital","city":"Jeonnam","zip":"519-763","country":"South Korea"},{"facility":"The Catholic University of Korea St. Vincent's Hospital","city":"Suwon","zip":"442-723","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Hospital Universitario Marques de Valdecilla","city":"Santander","state":"Cantabria","zip":"39008","country":"Spain","geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Consorcio Hospitalario Provincial de Castellon","city":"Castellon","state":"Castellon","zip":"12002","country":"Spain","geoPoint":{"lat":39.98567,"lon":-0.04935}},{"facility":"Hospital Universitario Virgen de La Arrixaca","city":"El Palmar","state":"Murcia","zip":"30120","country":"Spain","geoPoint":{"lat":37.93939,"lon":-1.16095}},{"facility":"Hospital Universitario de Canarias","city":"San Cristóbal de La Laguna","state":"Tenerife","zip":"3820","country":"Spain","geoPoint":{"lat":28.4853,"lon":-16.32014}},{"facility":"Hospital del Mar","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Santa Creu i Sant Pau","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Vall d'Hebron Institute of Oncology (VHIO), Barcelona","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"C.H. Regional Reina Sofia","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Complejo Hospitalario de Jaen","city":"Jaén","zip":"23007","country":"Spain","geoPoint":{"lat":37.76922,"lon":-3.79028}},{"facility":"Hospital Lucus Augusti","city":"Lugo","zip":"27003","country":"Spain","geoPoint":{"lat":43.00992,"lon":-7.55602}},{"facility":"Hospital Universitario La Paz","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario HM Sanchinarro-CIOCC","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitari i Politecnic La Fe de Valencia","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hosp Clinico Univ Lozano Blesa","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Changhua Christian Hospital","city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"Chang Gung Memorial Hospital Chiayi","city":"Putzui City","zip":"61363","country":"Taiwan"},{"facility":"Taichung Veterans General Hospital","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","zip":"00112","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Chang Gung Medical Foundation Linkou Branch","city":"Taoyuan","zip":"333","country":"Taiwan","geoPoint":{"lat":24.99368,"lon":121.29696}},{"facility":"MI Dnipropetrovsk City Multifield Clinical Hospital 4 of Dnipropetrovsk Regional Council","city":"Dnipropetrovsk","state":"Katerynoslav Governorate","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Communal Non profit Enterprise Regional Center of Oncology","city":"Kharkiv","state":"Kharkiv Governorate","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Municipal Institution Odesa Regional Oncology Dispensary","city":"Odesa","state":"KIEV Governorate","zip":"65055","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"Municipal Institution SubCarpathian ClinicalOncological Centre","city":"Ivano-Frankivsk","state":"Poltava Governorate","zip":"76018","country":"Ukraine","geoPoint":{"lat":48.92312,"lon":24.71248}},{"facility":"Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council","city":"Vinnytsia","state":"Vinnytsia Oblast","zip":"21018","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"CE Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council","city":"Kryvyi Rih","zip":"50048","country":"Ukraine","geoPoint":{"lat":47.90572,"lon":33.39404}},{"facility":"Kyiv City Clinical Oncological Center","city":"Kyiv","zip":"03115","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary","city":"Sumy","zip":"40022","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology","city":"Zaporizhzhya","zip":"69040","country":"Ukraine","geoPoint":{"lat":47.85167,"lon":35.11714}},{"facility":"Colchester General Hospital","city":"Colchester, Essex","zip":"CO4 5JL","country":"United Kingdom","geoPoint":{"lat":51.88921,"lon":0.90421}},{"facility":"St Bartholomew's Hospital","city":"London","zip":"EC1A 7BE","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"referencesModule":{"references":[{"pmid":"40446184","type":"DERIVED","citation":"Felip E, Altorki N, Zhou C, Vallieres E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study Investigators. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. J Clin Oncol. 2025 Jul 20;43(21):2343-2349. doi: 10.1200/JCO-24-01681. Epub 2025 May 30."},{"pmid":"37903590","type":"DERIVED","citation":"Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, Reck M, Liersch R, Kryzhanivska A, Oizumi S, Tanaka H, Hamm J, McCune SL, Bennett E, Gitlitz B, McNally V, Ballinger M, McCleland M, Zou W, Das Thakur M, Novello S. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. J Immunother Cancer. 2023 Oct;11(10):e007047. doi: 10.1136/jitc-2023-007047."},{"pmid":"37467930","type":"DERIVED","citation":"Felip E, Altorki N, Zhou C, Vallieres E, Martinez-Marti A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M, Belleli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17."},{"pmid":"35947027","type":"DERIVED","citation":"Mohindra NA, Patel JD. Top advances in lung cancer, 2021. Cancer. 2022 Oct 1;128(19):3434-3437. doi: 10.1002/cncr.34406. Epub 2022 Aug 10."},{"pmid":"34555333","type":"DERIVED","citation":"Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\\_sharing"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The study consists of 2 phases, an enrollment phase in which participants received up to 4 cycles of adjuvant cisplatin-based chemotherapy followed by randomized phase in which eligible participants were randomized to receive atezolizumab or best supportive care (BSC) i.e.no treatment.","recruitmentDetails":"A total of 1280 participants with resectable Stage IB-IIIA non-small cell lung cancer (NSCLC) were enrolled in this study. Participants took part in the study at 227 investigative sites across 22 countries. The study is still ongoing.","groups":[{"id":"FG000","title":"Enrollment Phase","description":"All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \\[non-squamous cell NSCLC only\\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred."},{"id":"FG001","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"FG002","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"periods":[{"title":"Enrollment Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1280"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Enrolled Safety-evaluable Population","comment":"Enrolled Safety-evaluable population included all eligible participants who were enrolled in the enrollment phase and who received at least one dose of chemotherapy (cisplatin, vinorelbine, docetaxel, gemcitabine, or pemetrexed), regardless of whether they are subsequently randomized or not.","achievements":[{"groupId":"FG000","numSubjects":"1269"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1005"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"275"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Symptomatic deterioration","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"86"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Reason not provided","reasons":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Disease relapse","reasons":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Randomized Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","comment":"NOTE: 507 eligible participants were randomized to receive atezolizumab in the randomization phase.","numSubjects":"507"},{"groupId":"FG002","comment":"NOTE: 498 eligible participants were randomized to receive BSC in the randomization phase.","numSubjects":"498"}]},{"type":"Randomized Safety Population","comment":"Randomized safety population included all randomized participants who received at least one dose of the study treatment and all randomized participants who were randomized to the control arm and did not receive any dose of atezolizumab but who had at least one post-baseline safety assessment.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"495"},{"groupId":"FG002","numSubjects":"495"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"507"},{"groupId":"FG002","numSubjects":"498"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"44"},{"groupId":"FG002","numSubjects":"47"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"Disease Relapse","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"154"},{"groupId":"FG002","numSubjects":"155"}]},{"type":"Ongoing","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"301"},{"groupId":"FG002","numSubjects":"282"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Enrolled population was defined as all eligible participants who were enrolled in the enrollment phase, regardless if they are subsequently randomized or not.","groups":[{"id":"BG000","title":"Enrollment Phase","description":"All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \\[non-squamous cell NSCLC only\\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1280"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.4","spread":"8.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"427"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"853"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"18"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1219"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"43"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"307"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"935"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"27"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","populationDescription":"Randomized ITT population was defined as all randomized participants with resected Stage IB \\[tumors ≥ 4 centimetres (cm)\\]-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 95 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"507"},{"groupId":"OG001","value":"498"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.6","lowerLimit":"52.4","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval (CI) was not estimable due to insufficient number of participants with events."},{"groupId":"OG001","value":"47.8","lowerLimit":"37.0","upperLimit":"65.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0683","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.848","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.710","ciUpperLimit":"1.013"}]},{"type":"PRIMARY","title":"DFS in All Randomized Stage II-IIIA Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in participants with disease stage II-IIIA. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","populationDescription":"Stage II-IIIA population was defined as all randomized participants with extent of disease as either Stage II or Stage IIIA, and is a subset of the ITT population. Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 95 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"},{"groupId":"OG001","value":"440"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","lowerLimit":"42.2","upperLimit":"NA","comment":"The upper limit of the 95% CI was not estimable due to insufficient number of participants with events."},{"groupId":"OG001","value":"40.8","lowerLimit":"31.4","upperLimit":"57.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.830","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.691","ciUpperLimit":"0.998"}]},{"type":"PRIMARY","title":"DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 ≥1% subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","populationDescription":"PD-L1 subpopulation, defined as ≥1% TC expression by the SP263 immunohistochemistry (IHC) assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \\& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 95 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"228"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","lowerLimit":"51.8","upperLimit":"NA","comment":"The upper limit of the 95% CI was not estimable due to insufficient number of participants with events."},{"groupId":"OG001","value":"37.3","lowerLimit":"30.1","upperLimit":"57.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.704","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.545","ciUpperLimit":"0.910"}]},{"type":"SECONDARY","title":"Overall Survival (OS) in the ITT Population","description":"OS was defined as the time from randomization to death from any cause.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2036-08","timeFrame":"Up to 20 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Disease-free Rate at Year 3 in ITT Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 3. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","populationDescription":"Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Year 3","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"507"},{"groupId":"OG001","value":"498"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.43","lowerLimit":"57.09","upperLimit":"65.77"},{"groupId":"OG001","value":"55.45","lowerLimit":"50.95","upperLimit":"59.95"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"5.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.28","ciUpperLimit":"12.23"}]},{"type":"SECONDARY","title":"Disease-free Rate at Year 3 in All Randomized Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","populationDescription":"Stage II-IIIA population was defined as all randomized participants with extent of disease as either Stage II or Stage III, and is a subset of the ITT population. Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Year 3","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"},{"groupId":"OG001","value":"440"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.30","lowerLimit":"54.61","upperLimit":"63.98"},{"groupId":"OG001","value":"52.64","lowerLimit":"47.83","upperLimit":"57.46"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"6.65","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.06","ciUpperLimit":"13.36"}]},{"type":"SECONDARY","title":"Disease-free Rate at Year 3 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","populationDescription":"PD-L1 subpopulation, defined as ≥ 1% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \\& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Year 3","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"228"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.72","lowerLimit":"56.54","upperLimit":"68.90"},{"groupId":"OG001","value":"52.05","lowerLimit":"45.35","upperLimit":"58.75"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"10.67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.56","ciUpperLimit":"19.79"}]},{"type":"SECONDARY","title":"Disease-free Rate at Year 5 in ITT Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","populationDescription":"Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Year 5","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"507"},{"groupId":"OG001","value":"498"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.96","lowerLimit":"47.45","upperLimit":"56.46"},{"groupId":"OG001","value":"46.48","lowerLimit":"41.91","upperLimit":"51.05"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"5.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.94","ciUpperLimit":"11.90"}]},{"type":"SECONDARY","title":"Disease-free Rate at Year 5 in All Randomized Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","populationDescription":"Stage II-IIIA population was defined as all randomized participants with extent of disease as either Stage II or Stage III, and is a subset of the ITT population. Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Year 5","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"},{"groupId":"OG001","value":"440"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.28","lowerLimit":"44.47","upperLimit":"54.10"},{"groupId":"OG001","value":"44.40","lowerLimit":"39.57","upperLimit":"49.24"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"4.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.94","ciUpperLimit":"11.70"}]},{"type":"SECONDARY","title":"Disease-free Rate at Year 5 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","populationDescription":"PD-L1 subpopulation, defined as ≥ 1% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \\& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Year 5","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"228"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.15","lowerLimit":"46.69","upperLimit":"59.61"},{"groupId":"OG001","value":"42.69","lowerLimit":"36.00","upperLimit":"49.38"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"10.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.16","ciUpperLimit":"19.76"}]},{"type":"SECONDARY","title":"DFS in the PD-L1 (SP263 ≥ 50% TC) Subpopulation Within the Stage II-IIIA Population","description":"DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.","populationDescription":"PD-L1 subpopulation, defined as ≥50% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \\& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 95 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."},{"id":"OG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median and the 95% CI was not estimable due to insufficient number of participants with events."},{"groupId":"OG001","value":"41.1","lowerLimit":"29.7","upperLimit":"NA","comment":"The upper limit of the 95% CI was not estimable due to insufficient number of participants with events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.503","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.332","ciUpperLimit":"0.761"}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a participant when administered a pharmaceutical product regardless of the causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2036-08","timeFrame":"Up to 20 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab","description":"The percentage of ATA (Also called anti-drug antibodies (ADA))-positive participants after drug administration were determined for participants exposed to atezolizumab. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.","populationDescription":"ADA evaluable population was defined as all randomized participants who received at least one dose of atezolizumab and who have at least one post-baseline ADA result.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Predose (Hour 0) on Day 1 of Cycles 2, 3, 4, 8, 16 (Cycle length = 21 days), at treatment discontinuation (TD) (up to 12 months), 120 days after last atezolizumab administration (up to 16 months)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"487"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2"}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentration (Cmax) of Atezolizumab","populationDescription":"PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"micrograms/millilitres (μg/ml)","timeFrame":"30 min post-infusion on Day 1 of Cycle 1 (Cycle length = 21 days)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"451"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":"124"}]}]}]},{"type":"SECONDARY","title":"Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab","populationDescription":"PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Number analyzed is the number of participants with data available for analyses at the specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/ml","timeFrame":"Prior to infusion on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (Cycle length = 21 days), at study discontinuation visit (up to 12 months), Day 120 post last dose of atezolizumab (up to 16 months)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"493"}]}],"classes":[{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"451"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":"123.5"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"446"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":"79.3"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"436"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":"58.4"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"419"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":"57.6"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"353"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":"40.6"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":"87.3"}]}]},{"title":"Treatment Discontinuation Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"404"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":"221.8"}]}]},{"title":"Day 120 Post Last Dose of Atezolizumab","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"352"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.58","spread":"794.8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 95 months","description":"Enrolled safety-evaluable population included patients in enrollment phase \\& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \\& randomized patients who were randomized to control arm \\& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.","eventGroups":[{"id":"EG000","title":"Enrollment Phase","description":"All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \\[non-squamous cell NSCLC only\\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred.","deathsNumAffected":19,"deathsNumAtRisk":1269,"seriousNumAffected":259,"seriousNumAtRisk":1269,"otherNumAffected":1153,"otherNumAtRisk":1269},{"id":"EG001","title":"Best Supportive Care (BSC)","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.","deathsNumAffected":155,"deathsNumAtRisk":495,"seriousNumAffected":42,"seriousNumAtRisk":495,"otherNumAffected":227,"otherNumAtRisk":495},{"id":"EG002","title":"Atezolizumab","description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","deathsNumAffected":154,"deathsNumAtRisk":495,"seriousNumAffected":88,"seriousNumAtRisk":495,"otherNumAffected":358,"otherNumAtRisk":495}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Sarcoidosis of lymph node","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Hypopituitarism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Secondary adrenocortical insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Vitreous haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Abdominal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":495}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":495}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Cholestasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Contrast media reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Immune-mediated adverse reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Sarcoidosis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Biliary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":495}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Otitis media chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":1269},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":495},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":495}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Viral myocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Comminuted fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Prescribed overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Urethral stricture traumatic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Acute myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Anal squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Intestinal metastasis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Langerhans' cell histiocytosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Squamous cell carcinoma of head and neck","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Urinary tract neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Axonal neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Cerebellar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":495}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Demyelinating polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Encephalitis autoimmune","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Intracranial haematoma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Dissociative disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Hallucination, visual","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Urinary tract obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Adnexal torsion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Alveolitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":495}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":495}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":495}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":495}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":38,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Myelosuppression","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Ventricular arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Otolithiasis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Gastrointestinal inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Large intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Varices oesophageal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Device related thrombosis","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bacterial abdominal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bacterial diarrhoea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Device related sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Diarrhoea infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Intervertebral discitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Oral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pneumonia staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Stitch abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Vascular device infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Vascular access complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Autonomic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Hypotonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Intercostal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Device occlusion","organSystem":"Product Issues","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Catatonia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Bronchopleural fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Chylothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pulmonary artery thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Pulmonary granuloma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Subcutaneous emphysema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Granulomatosis with polyangiitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Subclavian vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":422,"numAffected":357,"numAtRisk":1269},{"groupId":"EG001","numEvents":30,"numAffected":30,"numAtRisk":495},{"groupId":"EG002","numEvents":47,"numAffected":37,"numAtRisk":495}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":1269},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":495},{"groupId":"EG002","numEvents":36,"numAffected":33,"numAtRisk":495}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1269},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":495},{"groupId":"EG002","numEvents":61,"numAffected":54,"numAtRisk":495}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":226,"numAffected":181,"numAtRisk":1269},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":495},{"groupId":"EG002","numEvents":54,"numAffected":36,"numAtRisk":495}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1032,"numAffected":660,"numAtRisk":1269},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":495},{"groupId":"EG002","numEvents":44,"numAffected":31,"numAtRisk":495}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":301,"numAffected":234,"numAtRisk":1269},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":495},{"groupId":"EG002","numEvents":45,"numAffected":37,"numAtRisk":495}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":309,"numAffected":269,"numAtRisk":1269},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":495},{"groupId":"EG002","numEvents":41,"numAffected":33,"numAtRisk":495}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":86,"numAffected":75,"numAtRisk":1269},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":495},{"groupId":"EG002","numEvents":67,"numAffected":60,"numAtRisk":495}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":25,"numAtRisk":1269},{"groupId":"EG001","numEvents":65,"numAffected":50,"numAtRisk":495},{"groupId":"EG002","numEvents":44,"numAffected":33,"numAtRisk":495}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":27,"numAtRisk":1269},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":495},{"groupId":"EG002","numEvents":43,"numAffected":37,"numAtRisk":495}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":52,"numAtRisk":1269},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":495},{"groupId":"EG002","numEvents":71,"numAffected":54,"numAtRisk":495}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":43,"numAtRisk":1269},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":495},{"groupId":"EG002","numEvents":67,"numAffected":54,"numAtRisk":495}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":113,"numAffected":85,"numAtRisk":1269},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":495},{"groupId":"EG002","numEvents":36,"numAffected":29,"numAtRisk":495}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":36,"numAtRisk":1269},{"groupId":"EG001","numEvents":35,"numAffected":26,"numAtRisk":495},{"groupId":"EG002","numEvents":65,"numAffected":52,"numAtRisk":495}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":77,"numAtRisk":1269},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":495},{"groupId":"EG002","numEvents":39,"numAffected":28,"numAtRisk":495}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":101,"numAffected":93,"numAtRisk":1269},{"groupId":"EG001","numEvents":55,"numAffected":46,"numAtRisk":495},{"groupId":"EG002","numEvents":84,"numAffected":66,"numAtRisk":495}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":64,"numAtRisk":1269},{"groupId":"EG001","numEvents":33,"numAffected":32,"numAtRisk":495},{"groupId":"EG002","numEvents":35,"numAffected":31,"numAtRisk":495}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":22,"numAtRisk":1269},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":495},{"groupId":"EG002","numEvents":55,"numAffected":51,"numAtRisk":495}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":54,"numAtRisk":1269},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":495},{"groupId":"EG002","numEvents":58,"numAffected":48,"numAtRisk":495}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":128,"numAffected":84,"numAtRisk":1269},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":495},{"groupId":"EG002","numEvents":10,"numAffected":5,"numAtRisk":495}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":568,"numAffected":338,"numAtRisk":1269},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":495},{"groupId":"EG002","numEvents":33,"numAffected":21,"numAtRisk":495}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":67,"numAtRisk":1269},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":495},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":495}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":75,"numAffected":69,"numAtRisk":1269},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":495},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":495}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":389,"numAffected":317,"numAtRisk":1269},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":495},{"groupId":"EG002","numEvents":27,"numAffected":24,"numAtRisk":495}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":361,"numAffected":248,"numAtRisk":1269},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":495},{"groupId":"EG002","numEvents":27,"numAffected":20,"numAtRisk":495}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":66,"numAtRisk":1269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":495},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":495}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":367,"numAffected":187,"numAtRisk":1269},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":495},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":495}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":108,"numAffected":73,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":12,"numAffected":10,"numAtRisk":495}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":221,"numAffected":111,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":495}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":421,"numAffected":305,"numAtRisk":1269},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":495},{"groupId":"EG002","numEvents":28,"numAffected":23,"numAtRisk":495}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":70,"numAtRisk":1269},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":495},{"groupId":"EG002","numEvents":20,"numAffected":18,"numAtRisk":495}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":106,"numAffected":95,"numAtRisk":1269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":495},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":495}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":75,"numAtRisk":1269},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":495},{"groupId":"EG002","numEvents":21,"numAffected":21,"numAtRisk":495}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":142,"numAffected":89,"numAtRisk":1269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":495},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":495}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":183,"numAffected":181,"numAtRisk":1269},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":495},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":495}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsorâ€™s intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800 821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2024-05-24","uploadDate":"2024-12-12T14:43","filename":"Prot_000.pdf","size":6423753},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-06-30","uploadDate":"2024-12-12T14:43","filename":"SAP_001.pdf","size":748331}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Canada"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000594389","term":"atezolizumab"},{"id":"D002945","term":"Cisplatin"},{"id":"D000077235","term":"Vinorelbine"},{"id":"D000077143","term":"Docetaxel"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D014748","term":"Vinca Alkaloids"},{"id":"D046948","term":"Secologanin Tryptamine Alkaloids"},{"id":"D026121","term":"Indole Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D007211","term":"Indoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D054836","term":"Indolizidines"},{"id":"D007212","term":"Indolizines"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}